esonarimod has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (esonarimod) | Trials (esonarimod) | Recent Studies (post-2010) (esonarimod) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 33 | 1 | 8 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukushima, K; Inoue, T; Takeshita, K | 1 |
1 other study(ies) available for esonarimod and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages.
Topics: Animals; Antirheumatic Agents; Auranofin; Cell Division; Cell Line; Concanavalin A; Cysteine; Female; Hydrogen Peroxide; In Vitro Techniques; Interferon-gamma; Ionomycin; Lipopolysaccharides; Lymphocyte Activation; Lymphocytes; Macrophages; Mice; Mice, Inbred DBA; Nitric Oxide; Penicillamine; Phenylpropionates; Recombinant Proteins; Tetradecanoylphorbol Acetate | 2001 |